fbpx

Download Your Favorite Teams Schedule Here

×
WK
1
Fri, Dec 2
FINAL
Philadelphia
8
Halifax
18
Sat, Dec 3
FINAL
Vancouver
8
Toronto
19
Sat, Dec 3
FINAL
San Diego
15
New York
14
Sat, Dec 3
FINAL
Albany
11
Buffalo
10
Sat, Dec 3
FINAL
Rochester
16
Georgia
11
Sat, Dec 3
FINAL
Colorado
6
Saskatchewan
18
WK
2
Fri, Dec 9
20:30:00
Las Vegas
Panther City
Fri, Dec 9
22:00:00
Saskatchewan
San Diego
Sat, Dec 10
19:00:00
Toronto
Rochester
Sat, Dec 10
21:30:00
Vancouver
Calgary
WK
3
Fri, Dec 16
22:00:00
Calgary
Vancouver
Fri, Dec 16
22:30:00
Panther City
Las Vegas
Sat, Dec 17
19:00:00
Buffalo
Toronto
Sat, Dec 17
19:00:00
Rochester
Albany
Sat, Dec 17
19:00:00
Philadelphia
Georgia
Sat, Dec 17
19:30:00
Halifax
New York
Sat, Dec 17
20:00:00
Colorado
Panther City
WK
5
Fri, Dec 30
19:30:00
Halifax
Buffalo
Fri, Dec 30
21:00:00
San Diego
Calgary
Sat, Dec 31
21:00:00
Panther City
Saskatchewan
WK
6
Fri, Jan 6
22:30:00
Philadelphia
Las Vegas
Sat, Jan 7
19:00:00
Panther City
Rochester
Sat, Jan 7
19:00:00
Halifax
Albany
Sat, Jan 7
19:00:00
Buffalo
Georgia
Sat, Jan 7
19:30:00
Toronto
New York
Sat, Jan 7
22:00:00
Vancouver
San Diego
Sun, Jan 8
0:00:00
Calgary
Colorado
WK
7
Fri, Jan 13
18:30:00
Albany
Halifax
Fri, Jan 13
21:00:00
Saskatchewan
Colorado
Sat, Jan 14
19:00:00
Halifax
Toronto
Sat, Jan 14
19:00:00
Panther City
Philadelphia
Sat, Jan 14
19:30:00
Georgia
Buffalo
Sat, Jan 14
21:00:00
San Diego
Calgary
Sat, Jan 14
22:00:00
Las Vegas
Vancouver
Sun, Jan 15
15:00:00
Rochester
New York
WK
8
Fri, Jan 20
19:30:00
Buffalo
Rochester
Fri, Jan 20
22:30:00
Vancouver
Las Vegas
Sat, Jan 21
19:00:00
New York
Albany
Sat, Jan 21
19:00:00
Toronto
Philadelphia
WK
9
Fri, Jan 27
18:00:00
Rochester
Halifax
Fri, Jan 27
19:00:00
Buffalo
Philadelphia
Sat, Jan 28
19:30:00
Buffalo
New York
Sat, Jan 28
20:30:00
Las Vegas
Saskatchewan
Sat, Jan 28
21:00:00
Toronto
Calgary
Sat, Jan 28
21:00:00
San Diego
Colorado
Sat, Jan 28
22:00:00
Panther City
Vancouver
WK
10
Fri, Feb 3
21:00:00
Georgia
Colorado
Sat, Feb 4
18:00:00
Calgary
Halifax
Sat, Feb 4
19:00:00
New York
Toronto
Sat, Feb 4
19:00:00
Albany
Philadelphia
Sat, Feb 4
19:30:00
Rochester
Buffalo
Sat, Feb 4
22:00:00
Panther City
San Diego
Sat, Feb 4
22:00:00
Saskatchewan
Vancouver
Sat, Feb 4
22:30:00
Colorado
Las Vegas
WK
11
Fri, Feb 10
19:30:00
Toronto
Georgia
Fri, Feb 10
21:00:00
Saskatchewan
Calgary
Sat, Feb 11
19:00:00
Halifax
Rochester
Sat, Feb 11
19:30:00
Albany
New York
Sat, Feb 11
20:00:00
Vancouver
Panther City
Sat, Feb 11
21:00:00
Colorado
Calgary
WK
12
Fri, Feb 17
22:00:00
Saskatchewan
San Diego
Fri, Feb 17
22:00:00
Calgary
Vancouver
Sat, Feb 18
19:00:00
Georgia
Toronto
Sat, Feb 18
19:00:00
Las Vegas
Albany
Sat, Feb 18
19:30:00
Philadelphia
Buffalo
Sat, Feb 18
20:00:00
Colorado
Panther City
Sun, Feb 19
13:00:00
New York
Halifax
WK
13
Fri, Feb 24
21:00:00
Panther City
Colorado
Fri, Feb 24
22:30:00
Calgary
Las Vegas
Sat, Feb 25
19:00:00
New York
Rochester
Sat, Feb 25
19:00:00
Albany
Georgia
Sat, Feb 25
20:00:00
Vancouver
Saskatchewan
WK
14
Fri, Mar 3
18:30:00
Buffalo
Halifax
Fri, Mar 3
21:00:00
Las Vegas
San Diego
Sat, Mar 4
11:30:00
New York
Philadelphia
Sat, Mar 4
19:00:00
Rochester
Toronto
Sat, Mar 4
19:00:00
Georgia
Albany
Sat, Mar 4
20:00:00
Saskatchewan
Panther City
Mon, Mar 6
19:00:00
Toronto
Philadelphia
WK
15
Fri, Mar 10
19:30:00
Halifax
Buffalo
Fri, Mar 10
21:00:00
Calgary
Colorado
Sat, Mar 11
19:00:00
Albany
Toronto
Sat, Mar 11
19:30:00
Philadelphia
New York
Sat, Mar 11
20:30:00
San Diego
Saskatchewan
Sat, Mar 11
22:30:00
Vancouver
Las Vegas
Sun, Mar 12
16:00:00
Rochester
Georgia
WK
16
Fri, Mar 17
21:00:00
Saskatchewan
Calgary
Fri, Mar 17
22:00:00
San Diego
Vancouver
Sat, Mar 18
11:00:00
Georgia
Philadelphia
Sat, Mar 18
18:00:00
Toronto
Halifax
Sat, Mar 18
19:30:00
Albany
New York
Sat, Mar 18
19:30:00
Colorado
Buffalo
Sat, Mar 18
20:00:00
Las Vegas
Panther City
Sun, Mar 19
15:00:00
Philadelphia
Rochester
WK
17
Fri, Mar 24
20:30:00
San Diego
Panther City
Sat, Mar 25
19:00:00
Toronto
Albany
Sat, Mar 25
19:00:00
Halifax
Philadelphia
Sat, Mar 25
19:30:00
Georgia
New York
Sat, Mar 25
21:30:00
Calgary
Saskatchewan
Sat, Mar 25
22:00:00
Buffalo
San Diego
Sat, Mar 25
22:00:00
Colorado
Vancouver
Sat, Mar 25
22:30:00
Rochester
Las Vegas
WK
18
Fri, Mar 31
20:00:00
New York
Georgia
Fri, Mar 31
21:00:00
Las Vegas
Colorado
Fri, Mar 31
22:00:00
Calgary
San Diego
Sat, Apr 1
19:00:00
Buffalo
Toronto
Sat, Apr 1
20:00:00
Albany
Panther City
Sat, Apr 1
21:30:00
Vancouver
Saskatchewan
Sun, Apr 2
13:00:00
Georgia
Halifax
Sun, Apr 2
18:00:00
Rochester
Philadelphia
WK
19
Sat, Apr 8
19:00:00
Albany
Rochester
Sat, Apr 8
19:00:00
Saskatchewan
Georgia
Sat, Apr 8
21:00:00
Panther City
Calgary
Sat, Apr 8
21:00:00
Vancouver
Colorado
Sat, Apr 8
22:30:00
San Diego
Las Vegas
WK
20
Fri, Apr 14
21:00:00
Las Vegas
Calgary
Fri, Apr 14
21:00:00
San Diego
Colorado
Sat, Apr 15
19:00:00
Philadelphia
Toronto
Sat, Apr 15
19:00:00
Georgia
Albany
Sat, Apr 15
19:30:00
New York
Buffalo
Sat, Apr 15
21:30:00
Halifax
Saskatchewan
Sat, Apr 15
22:00:00
Panther City
Vancouver
WK
21
Fri, Apr 21
20:30:00
Calgary
Panther City
Sat, Apr 22
18:00:00
New York
Halifax
Sat, Apr 22
19:00:00
Georgia
Rochester
Sat, Apr 22
20:00:00
Toronto
Buffalo
Sat, Apr 22
21:30:00
Colorado
Saskatchewan
Sat, Apr 22
22:00:00
Las Vegas
San Diego
Sun, Apr 23
15:00:00
Philadelphia
Albany
WK
22
Sat, Apr 29
19:00:00
Philadelphia
Rochester
Sat, Apr 29
19:00:00
Buffalo
Albany
Sat, Apr 29
19:00:00
Halifax
Georgia
Sat, Apr 29
22:00:00
Colorado
San Diego
Sat, Apr 29
22:00:00
New York
Vancouver
Sat, Apr 29
22:30:00
Saskatchewan
Las Vegas
Powered By
MGM Logo
Scores / Schedule
Stories/Op-Ed

National Lacrosse League and Egalet Corporation Announce Educational Partnership Around A Non-Narcotic Pain Option and Responsible Pain Management

The National Lacrosse League (NLL), the largest men’s professional indoor lacrosse league in North America, and Egalet Corporation (Nasdaq: EGLT), a specialty pharmaceutical company focused on developing innovative treatments for pain and other conditions, today announced a partnership focused on physician education around responsible pain management. The two-year agreement will include a product symposium at the 2017 NLL Medical Summit to educate physicians on how to help treat pain with a nonsteroidal anti-inflammatory drug (NSAID), which is also a non-narcotic pain management option. Egalet’s product SPRIX® (ketorolac tromethamine) Nasal Spray, is an NSAID approved in the United States for the short term (up to 5 days) management of moderate to moderately severe pain in adults that requires analgesia at the opioid level.

 

“The health and safety of our players is paramount and we’re proud to partner with Egalet, a company committed to providing innovative pain medications,” said Nick Sakiewicz, Commissioner of the NLL. “Box lacrosse is a fast-paced and physical sport and given NLL’s commitment to the safety and well-being of our players, it is critical that our team physicians are aware of options like SPRIX Nasal Spray.”

 

Egalet is the first pharmaceutical partner for the NLL. Player health is overseen by an extensive base of private practice healthcare providers including primary care, orthopedic surgeons, neurologists and dentists.
“Egalet is committed to responsible pain management education and increasing awareness of a non-narcotic pain medication as a treatment option for moderate to moderately severe acute pain in adults,” said Pat Shea, chief commercial officer of Egalet. “Together with NLL, we can help educate healthcare providers about a non-narcotic treatment option for acute pain.”

 

About the National Lacrosse League

The National Lacrosse League (NLL) is North America’s premier professional indoor lacrosse league. Founded in 1986, the NLL ranks third in average attendance for pro indoor sports worldwide, behind only the NHL and NBA. The League comprises nine franchises across the United States and Canada: Buffalo Bandits, Calgary Roughnecks, Colorado Mammoth, Georgia Swarm, New England Black Wolves, Rochester Knighthawks, Saskatchewan Rush, Toronto Rock and Vancouver Stealth. The 2017 NLL regular season, commemorating the League’s 31st year, is underway. For more information, visit NLL.com and find the NLL on Facebook, Instagram and Twitter.

 

To stay connected to your team, the latest scores and developments in the National Lacrosse League, please visit www.NLL.com.

 

About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. To learn more about SPRIX or for full prescribing information on SPRIX, including the boxed warning and medication guide, please visit sprix.com. For additional information on Egalet, please visit egalet.com.

IMPORTANT SAFETY INFORMATION ABOUT SPRIX NASAL SPRAY

 

WARNING: RISK OF SERIOUS CARDIOVASCULAR

AND GASTROINTESTINAL EVENTS

Cardiovascular Thrombotic Events

·    Nonsteroidal anti-inflammatory drugs (NSAIDS) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.

·    SPRIX® is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.

Gastrointestinal Bleeding, Ulceration, and Perforation

·    NSAIDS cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.

Indications and Usage

SPRIX® (ketorolac tromethamine) is indicated in adult patients for the short term (up to 5 days) management of moderate to moderately severe pain that requires analgesia at the opioid level.

Contraindications

SPRIX is contraindicated in the following patients:

  • Known hypersensitivity to ketorolac or any components of the drug product.
  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.
  • In the setting of coronary artery bypass graft (CABG) surgery.
  • Use in patients with active peptic ulcer disease or with recent gastrointestinal bleeding or perforation.
  • Use as a prophylactic analgesic before any major surgery.
  • Use in patients with advanced renal disease or patients at risk for renal failure due to volume depletion.
  • Use in labor and delivery. May adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of uterine hemorrhage.
  • Use in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, or those for whom hemostasis is critical.
  • Concomitant use with probenecid or pentoxifylline.

Warnings and Precautions

Cardiovascular Thrombotic Events: increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Contraindicated in the setting of CABG. Patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment.

Gastrointestinal Bleeding, Ulceration, and Perforation: contraindicated in patients with active peptic ulcers and/or GI bleeding and in patients with recent gastrointestinal bleeding or perforation. Can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms. Patients with a prior history of peptic ulcer disease and/or GI bleeding who used NSAIDs had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.

Hepatotoxicity: Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop.

Hypertension: NSAIDs, including SPRIX, can lead to new onset or worsening of preexisting hypertension. Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure.

Heart Failure and Edema: Avoid use of SPRIX in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure.

Renal Toxicity and Hyperkalemia: Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of SPRIX in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function.

Anaphylactic Reactions: Seek emergency help if an anaphylactic reaction occurs.

Exacerbation of Asthma Related to Aspirin Sensitivity: Contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without known aspirin sensitivity).

Serious Skin Reactions: NSAIDs, including SPRIX, can cause serious skin reactions, which can be fatal. Discontinue SPRIX at first appearance of skin rash or other signs of hypersensitivity.

Premature Closure of Fetal Ductus Arteriosus: Avoid use in pregnant women starting at 30 weeks gestation.

Hematologic Toxicity: Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia. Do not use SPRIX in patients for whom hemostasis is critical.

Limitations of Use: SPRIX should not be used concomitantly with IM/IV or oral ketorolac, aspirin, or other NSAIDs.

Adverse Reactions

Serious adverse reactions include: cardiovascular thrombotic events; GI bleeding, ulceration and perforation; hepatotoxicity; hypertension; heart failure and edema; renal toxicity and hyperkalemia; anaphylactic reactions; serious skin reactions; hematologic toxicity.

The most common adverse reactions (incidence ≥2%) in patients treated with SPRIX and occurring at a rate at least twice that with placebo include: nasal discomfort; rhinalgia; increased lacrimation; throat irritation; oliguria; rash; bradycardia; decreased urine output; increased ALT and/or AST; hypertension; rhinitis.

In controlled clinical trials in major surgery, primarily knee and hip replacements and abdominal hysterectomies, 1.5% of patients treated with SPRIX experienced serious adverse events of bleeding or hematoma at the operative site versus 0.4% of patients treated with placebo who experienced hematoma.

In patients taking ketorolac or other NSAIDs in clinical trials, the most frequently reported adverse reactions in approximately 1% to 10% of patients are:

Gastrointestinal (GI): abdominal pain, constipation/diarrhea, dyspepsia, flatulence, GI fullness, GI ulcers (gastric/duodenal), gross bleeding/perforation, heartburn, nausea (incidence >10%), stomatitis, vomiting.

Other: abnormal renal function, anemia, dizziness, drowsiness, edema, elevated liver enzymes, headache (incidence >10%), hypertension, increased bleeding time, injection site pain, pruritus, purpura, rash, tinnitus, sweating.

Drug Interactions

Drugs that interfere with hemostasis: increased risk of serious bleeding with use of anticoagulants, antiplatelet agents, selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs); concomitant use with pentoxifylline is contraindicated.

ACE inhibitors, angiotensin receptor blockers (ARBs), and beta-blockers: may diminish the antihypertensive effect of these drugs; monitor blood pressure.

ACE Inhibitors and ARBs: In elderly, volume depleted, or those with renal impairment may result in deterioration of renal function; monitor for signs of worsening renal function.

Diuretics: reduces the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients.

Digoxin: has been reported to increase the serum concentration and prolong the half-life of digoxin.

Use in Specific Populations

Pregnancy: Use of NSAIDs during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs in pregnant women starting at 30 weeks gestation.

Infertility: NSAIDs are associated with reversible infertility. Consider withdrawal of SPRIX in women who have difficulties conceiving.

Overdosage

Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression, and coma have occurred, but were rare.

17-SP-021

Safe Harbor
Statements included in this press release (including but not limited to upcoming milestones) that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of Egalet’s clinical trials, including the timely recruitment of trial subjects and meeting the timelines therefor; Egalet’s ability to obtain and maintain regulatory approval of Egalet’s products and  product candidates and any regulatory action involving Egalet’s products; Egalet’s ability to maintain the intellectual property position of Egalet’s products and product candidates; Egalet’s ability to identify and reliance upon qualified third parties to manufacture its products; Egalet’s ability to service its debt obligations; Egalet’s ability to find and hire qualified sales professionals; the receptivity in the marketplace and among physicians to Egalet’s products; the success of products which compete with Egalet’s that are or become available; general market conditions; and other risk factors described in Egalet’s filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

Contact:

Victoria Davis

W2O Group on behalf of Egalet

(410) 279-3049

[email protected]

Mike Pettit

National Lacrosse League

212.764.1390 212.76×170

[email protected]

 

 

NLL